Elamipretide for dry AMD targets mitochondria, protects photoreceptors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Reenie McCarthy, CEO of Stealth BioTherapeutics, discusses elamipretide for the treatment of dry age-related macular degeneration.

According to McCarthy, elamipretide is an at-home once-daily subcutaneous injection designed to restore mitochondrial bioenergetics and protect photoreceptors, thus possibly improving vision. In a phase 2 clinical trial, elamipretide demonstrated a 43% protective effect on the progressive loss of photoreceptors.

“Maybe even more importantly, we saw a protective effect on at-risk photoreceptors,” McCarthy said. “These are photoreceptors that aren’t yet dead but are dysfunctional.”

Published by:

Sources/Disclosures

Collapse

Source:

Rezaei KA. Dry AMD. Presented at: Retina World Congress; May 8-11, 2025; Fort Lauderdale, Florida.

Disclosures:
McCarthy reports being CEO of Stealth BioTherapeutics.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio